文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性第三年管理:TREX-AMD随机试验最终结果

Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial.
PubMed 文献 · Br J Ophthalmol · 2017-08-04

TREX-AMD随机试验第三年最终结果显示:初始随机至每月给药组转为PRN后最佳矫正视力从第24个月+10.5个字母降至第36个月+5.4个字母(p=0.09);初始随机至TREX组中9例(23%)在达到12周访视间隔后转为PRN,106次PRN访视中仅需4次(4%)玻璃体腔注射,该亚组视力轨迹较差;继续TREX者第36个月平均视力增益+5.0个字母。

要点

  • 每月给药组转为PRN后最佳矫正视力从+10.5个字母降至+5.4个字母(p=0.09)。
  • TREX组中9例(23%)达到12周间隔后转为PRN,106次PRN访视仅需4次(4%)注射。
  • 继续TREX者第36个月平均视力增益+5.0个字母,结局更有利。

核心结论

  • 初始随机至每月给药组转为PRN后最佳矫正视力出现下降。
  • 初始随机至TREX组中在达到12周访视间隔后转为PRN者,额外治疗需求总体较低。

研究设计与样本

  • TREX-AMD随机试验第三年最终结果分析,治疗初治新生血管性AMD受试者按1:2随机至每月给药组或TREX组并管理至2年。
  • 第三年中,随机至每月给药组者按PRN管理,随机至TREX组者继续TREX给药或在达到12周访视间隔后转为PRN。
  • 共入组60例受试者,46例(77%)完成第36个月访视。

主要发现

  • 每月给药组转为PRN后最佳矫正视力从第24个月+10.5个字母降至第36个月+5.4个字母(p=0.09)。
  • 每月给药组转为PRN后第3年有3例(15%)受试者无需给药,243次可能PRN注射中实际给予114次(47%),第3年平均注射6.1次。
  • TREX组中9例(23%)转为PRN,106次PRN访视中给予4次(4%)玻璃体腔注射,该亚组视力轨迹较其余受试者差。
  • 继续TREX的受试者结局更有利,第36个月平均视力增益+5.0个字母。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: Prospectively evaluate outcomes in the third year of neovascular age-related macular degeneration (AMD) management using ranibizumab with continued treat and extend (TREX) dosing compared with monthly visits with retreatment upon evidence of exudative disease activity (PRN, pro re nata). METHODS: Subjects with treatment-naïve neovascular AMD were randomised 1:2 to Monthly or TREX and managed through 2 years. In the third year, subjects randomised to Monthly were managed PRN while subjects randomised to TREX were continued on TREX dosing or transitioned to PRN after achieving an interval of 12 weeks between visits. RESULTS: Sixty subjects enrolled and 46 (77%) completed month 36 (M36). Transition from Monthly to PRN was associated with a decline in best corrected visual acuity (BCVA) (+10.5 letters (month 24) to +5.4 (M36, p=0.09)); three (15%) subjects required no dosing during year 3, and 47% (114/243) of possible PRN injections were delivered, yielding a mean of 6.1 injections during year 3. Among the 9 (23%) TREX subjects transitioned to PRN, the need for ongoing anti-vascular endothelial growth factor retreatments was small, with 4 (4%) intravitreal injections being delivered among 106 PRN visits; this subgroup displayed an inferior BCVA trajectory compared with the remainder of subjects. Outcomes among subjects continued on TREX were more favourable, with a mean gain of +5.0 letters at M36. CONCLUSIONS: Upon transition to PRN, subjects randomised to monthly dosing experienced a decline in BCVA. Among subjects initially randomised to TREX who transitioned to PRN after achieving a 12-week interval between visits, the overall need for additional treatment was low. TRIAL REGISTRATION NUMBER: NCT01748292, Results.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Wykoff CC, Ou WC, Croft DE, et al. Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. Br J Ophthalmol. 2017. PMID: 28779006. doi:10.1136/bjophthalmol-2017-310822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。